Real-World Data Shows Long-Term Stability for Leqembi Patients

The retrospective study, which analyzed 432 patients across 13 clinical sites in the United States, found that 75.9% of participants maintained their baseline disease stage, while 6.6% experienced an improvement in their condition. These results remained consistent across diverse demographics, including variations in sex, race, ethnicity, and APOE genotype, confirming the durability of the treatment in routine medical practice.

Clinicians observed that 87% of patients opted to continue their Leqembi regimen. Safety profiles mirrored those reported in the drug's original FDA-approved labeling, with amyloid-related imaging abnormalities (ARIA) occurring in 12.3% of the study population. Most of these cases were identified as asymptomatic or mild in radiographic severity. Notably, the incidence of ARIA did not increase among the 24.5% of patients who were concurrently receiving antithrombotic medications. These findings offer a comprehensive look at how the therapy performs in varied clinical settings, supporting the transition toward long-term maintenance protocols.